InnoCare Pharma announced that the first patient dosing in the clinical trial of ICP-B208, its novel ADC targeting CDH17

CAR-T Digest - August 2020

6 July 2026: InnoCare Pharma announced that the first patient dosing in the clinical trial of ICP-B208, its novel ADC targeting CDH17

InnoCare Pharma has announced the successful first patient dosing of ICP-B208, a novel CDH17-targeted antibody-drug conjugate, marking the clinical entry of a potentially first-in-class ADC designed to address multiple gastrointestinal malignancies with high unmet medical need
The initiation of clinical evaluation represents an important milestone for InnoCare’s expanding ADC pipeline, following the advancement of its B7-H3-targeted ADC ICP-B794, and highlights the company’s commitment to building a differentiated portfolio of next-generation oncology therapeutics
CDH17 is an emerging ADC target that is highly expressed in several gastrointestinal cancers, including colorectal, gastric, pancreatic, and biliary tract cancers, where it plays a key role in tumor proliferation, migration, and metastasis. Currently, no CDH17-targeted ADC has been approved globally, underscoring the novelty of the program

ICP-B208 was developed using InnoCare’s proprietary ADC platform and comprises a humanized anti-CDH17 antibody linked via a protease-cleavable linker to the company’s proprietary high-potency payload, enabling selective delivery of cytotoxic therapy to tumor cells while minimizing off-target toxicity
Strategically, the first patient dosing of ICP-B208 expands InnoCare’s presence in the rapidly evolving ADC landscape, strengthens its differentiated gastrointestinal oncology pipeline, and positions the company among the early developers pursuing CDH17 as a next-generation ADC target

For full story click here